Technical Analysis for INZY - Inozyme Pharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical INZY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 1.60% | |
| Down 3 Days in a Row | Weakness | 1.60% | |
| Down 4 Days in a Row | Weakness | 1.60% | |
| Narrow Range Bar | Range Contraction | 0.16% | |
| NR7 | Range Contraction | 0.16% | |
| Down 3 Days in a Row | Weakness | 0.16% | |
| 20 DMA Resistance | Bearish | -1.19% | |
| Multiple of Ten Bearish | Other | -1.19% | |
| Fell Below 20 DMA | Bearish | -4.75% | |
| Fell Below 50 DMA | Bearish | -4.75% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 2% | 16 minutes ago |
| Down 2 % | 36 minutes ago |
| Up 1% | about 3 hours ago |
| 60 Minute Opening Range Breakout | about 5 hours ago |
| Down 1% | about 6 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Pharmaceutical Industry Disease Pharmacy Molecular Biology Specialty Drugs Genetic Disease Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Pharmaceutical Industry Disease Pharmacy Molecular Biology Specialty Drugs Genetic Disease Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 31.6499 |
| 52 Week Low | 16.1 |
| Average Volume | 73,233 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 20.44 |
| 20-Day Moving Average | 19.91 |
| 10-Day Moving Average | 19.58 |
| Average True Range | 1.36 |
| ADX | 11.91 |
| +DI | 19.08 |
| -DI | 21.51 |
| Chandelier Exit (Long, 3 ATRs ) | 18.89 |
| Chandelier Exit (Short, 3 ATRs ) | 21.62 |
| Upper Bollinger Band | 22.73 |
| Lower Bollinger Band | 17.09 |
| Percent B (%b) | 0.29 |
| BandWidth | 28.33 |
| MACD Line | -0.38 |
| MACD Signal Line | -0.39 |
| MACD Histogram | 0.0081 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 20.19 | ||||
| Resistance 3 (R3) | 20.29 | 19.91 | 19.95 | ||
| Resistance 2 (R2) | 19.91 | 19.54 | 19.86 | 19.87 | |
| Resistance 1 (R1) | 19.33 | 19.32 | 19.14 | 19.23 | 19.79 |
| Pivot Point | 18.95 | 18.95 | 18.86 | 18.90 | 18.95 |
| Support 1 (S1) | 18.37 | 18.58 | 18.18 | 18.27 | 17.71 |
| Support 2 (S2) | 17.99 | 18.36 | 17.94 | 17.63 | |
| Support 3 (S3) | 17.41 | 17.99 | 17.55 | ||
| Support 4 (S4) | 17.31 |
